Royalty Pharma Reports Q4 and Full Year 2025 Results
Royalty Pharma (RPRX) reported strong financial performance for Q4 and full year 2025, with significant increases in Portfolio Receipts, Adjusted EBITDA, and Portfolio Cash Flow. The company deployed $2.6 billion in royalty transactions and repurchased $1.2 billion in shares, while also raising its quarterly dividend. For 2026, Royalty Pharma projects continued growth in Portfolio Receipts and anticipates pivotal study results to drive additional value.
Royalty Pharma EVP Coyne sells $10.3 million in shares By Investing.com
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold 237,531 shares of Class A Ordinary Shares between February 2nd and February 4th, 2026, totaling over $10.3 million. These transactions were executed under a 10b5-1 plan and occurred in multiple tranches at varying prices. The article also notes recent company activities including a record funding market year, a dividend increase, and an acquisition.
Royalty Pharma EVP Coyne sells $10.3 million in shares By Investing.com
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold over $10.3 million in Class A Ordinary Shares between February 2nd and February 4th, 2026, through multiple transactions ranging from $42.0839 to $43.2928 per share. These sales were executed under a 10b5-1 plan adopted in August 2025. The company also reported a record year for the royalty funding market in 2025, increased its quarterly dividend, and completed a significant acquisition of the Evrysdi royalty.
Royalty Pharma EVP Coyne sells $10.3 million in shares
Terrance P. Coyne, Executive Vice President and CFO of Royalty Pharma plc, sold over $10.3 million worth of Class A Ordinary Shares between February 2nd and February 4th, 2026. These transactions were executed under a pre-arranged 10b5-1 plan. The article also notes recent company achievements, including a record year for the royalty funding market and an increase in its quarterly dividend.
Royalty Pharma EVP Coyne sells $10.3 million in shares By Investing.com
Terrance P. Coyne, Executive Vice President and CFO of Royalty Pharma plc, sold 237,531 Class A Ordinary Shares for over $10.3 million between February 2nd and February 4th, 2026. These transactions were executed via a 10b5-1 plan and represent a significant divestiture. The company recently reported a record year for royalty funding, a dividend increase, and completed a major acquisition, leading to an analyst upgrade from UBS.
Urist Marshall, royalty pharma EVP, sells $821,810 in shares
Urist Marshall, EVP of Research & Investments at Royalty Pharma PLC, sold 20,000 Class A Ordinary Shares for approximately $821,810 on January 30, 2026. This transaction was executed under a pre-arranged 10b5-1 trading plan. Despite the sale, Royalty Pharma recently announced a record year in royalty funding, increased its quarterly dividend, and made a significant acquisition of royalty rights for the spinal muscular atrophy treatment, Evrysdi.
Urist Marshall, royalty pharma EVP, sells $821,810 in shares By Investing.com
Urist Marshall, EVP of Research & Investments at Royalty Pharma PLC, sold 20,000 Class A Ordinary Shares worth approximately $821,810 on January 30, 2026. This transaction was conducted under a pre-arranged 10b5-1 trading plan. The company recently reported a record year in royalty funding, increased its quarterly dividend, and acquired the remaining royalty on the spinal muscular atrophy treatment, Evrysdi, for $240 million upfront.
Urist Marshall, royalty pharma EVP, sells $821,810 in shares By Investing.com
Urist Marshall, Executive Vice President, Research & Investments at Royalty Pharma PLC, sold 20,000 Class A Ordinary Shares for approximately $821,810 on January 30, 2026. This sale was conducted under a pre-arranged 10b5-1 trading plan. In other news, Royalty Pharma had a record year in royalty funding in 2025, increased its quarterly dividend, and acquired PTC Therapeutics' remaining royalty on Evrysdi for $240 million upfront, prompting UBS to upgrade the stock to Buy.
Urist Marshall, royalty pharma EVP, sells $821,810 in shares
Marshall Urist, EVP at Royalty Pharma (NASDAQ:RPRX), sold 20,000 Class A Ordinary Shares for approximately $821,810 on January 30, 2026. This transaction was part of a pre-arranged trading plan. Royalty Pharma also reported a record year in royalty funding, increased its quarterly dividend, and made strategic acquisitions including a royalty on PTC Therapeutics' Evrysdi.
Royalty Pharma EVP Coyne sells shares worth $2.7 million
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold 69,582 Class A Ordinary Shares for approximately $2.7 million on January 20, 2026. These sales were conducted under a pre-arranged 10b5-1 trading plan. The article also highlights Royalty Pharma's strong performance in 2025, including a record $10 billion in the royalty funding market and significant acquisitions.
Royalty Pharma EVP Coyne sells shares worth $2.7 million By Investing.com
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold 69,582 Class A Ordinary Shares worth approximately $2.7 million on January 20, 2026. The sales were made under a pre-arranged 10b5-1 trading plan. In other news, Royalty Pharma reported a record year for the royalty funding market in 2025 and increased its quarterly dividend.
Royalty Pharma EVP Coyne sells shares worth $2.7 million
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold 69,582 Class A Ordinary Shares for approximately $2.7 million on January 20, 2026, through a pre-arranged trading plan. This transaction further details his remaining indirect and direct holdings in the company. In other news, Royalty Pharma maintained leadership in the royalty funding market in 2025, increased its quarterly dividend, and expanded its royalty interests with significant acquisitions of rights to Evrysdi and two cancer therapies.
Royalty Pharma plc to Release Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
Royalty Pharma plc announced it will release its fourth quarter and full year 2025 financial results on February 11, 2026, before U.S. markets open. A conference call and webcast will follow at 8:00 a.m. Eastern Time, with a replay available for 30 days. The company, founded in 1996, is a major buyer of biopharmaceutical royalties and funds innovation across the industry, holding royalties for over 35 commercial products and 20 development-stage candidates.
Urist Marshall, evp at Royalty Pharma, sells $815k in shares
Urist Marshall, Executive Vice President at Royalty Pharma, sold 20,000 Class A Ordinary Shares for approximately $815,634 on January 9, 2026, under a pre-arranged trading plan. Despite this insider selling, the company has shown aggressive share buybacks, boasts a "GREAT" financial health rating according to InvestingPro, and has raised its dividend for six consecutive years. Royalty Pharma recently reported a record year for the royalty funding market in 2025 and strategically acquired royalty interests in Roche’s Evrysdi and two cancer therapies.
Urist Marshall, evp at Royalty Pharma, sells $815k in shares By Investing.com
Marshall Urist, EVP at Royalty Pharma, sold 20,000 Class A Ordinary Shares worth approximately $815,634 on January 9, 2026, though the company has been aggressively buying back shares. Royalty Pharma, with a $23.3 billion market cap, has raised its dividend for six consecutive years and maintained a significant market share in the royalty funding market in 2025. The company also recently made strategic acquisitions of royalty interests in Roche’s Evrysdi and two cancer therapies.
Urist Marshall, evp at Royalty Pharma, sells $815k in shares
Urist Marshall, Executive Vice President at Royalty Pharma PLC, sold 20,000 Class A Ordinary Shares worth approximately $815,634 on January 9, 2026, under a pre-arranged trading plan. Despite this insider selling, the company has been aggressively buying back shares and has raised its dividend for six consecutive years. Royalty Pharma reported a record year for the royalty funding market in 2025, deploying $2.6 billion in capital, and strategically acquired royalty interests in Roche's Evrysdi and two cancer therapies.
Urist Marshall, evp at Royalty Pharma, sells $815k in shares
Urist Marshall, EVP at Royalty Pharma (NASDAQ: RPRX), sold 20,000 Class A Ordinary Shares for approximately $815,634 on January 9, 2026, executed under a pre-arranged trading plan. Despite this insider sale, the company has been aggressively buying back shares. Royalty Pharma recently announced a record year for the royalty funding market in 2025, increased its dividend, and made strategic acquisitions, including 100% ownership of the royalty interest in Roche’s Evrysdi.
Royalty Pharma Insider Sold Shares Worth $815,634, According to a Recent SEC Filing
An insider at Royalty Pharma plc (NASDAQ: RPRX) recently sold shares valued at $815,634, as disclosed in a new SEC filing. This transaction is part of the ongoing insider activity observed within the biopharmaceutical royalties company. The article also provides a summary of recent news for Royalty Pharma, including dividend declarations and new royalty acquisition agreements.
Royalty Pharma and Teva Pharmaceuticals Announce Up to $500 Million Funding Agreement for TEV-‘408 Development
Royalty Pharma and Teva Pharmaceuticals have entered an agreement where Royalty Pharma will provide up to $500 million to fund the development of Teva's anti-IL-15 antibody, TEV-‘408. This funding aims to accelerate the clinical trials for TEV-‘408, which is being investigated for vitiligo and celiac disease, starting with $75 million for a Phase 2b study in 2026. The collaboration highlights Teva's commitment to addressing unmet medical needs in autoimmune diseases and its "Pivot to Growth" strategy.
Assessing Royalty Pharma (RPRX) Valuation After Dividend Increase And Raised Full Year Guidance
Royalty Pharma (RPRX) has increased its quarterly dividend by 6.8% to US$0.235 per Class A share and raised its full-year guidance, leading to renewed attention on its valuation. While the current share price of US$40.17 is considered undervalued by some narratives, with a fair value around US$45.98, its P/E ratio of 22.4x is higher than the US pharmaceuticals average, suggesting a potential valuation risk. The company's future hinges on its cash flow management, deal pipeline, and operational efficiencies.
Royalty Pharma gives shareholders a 6.8% raise in quarterly payouts
Royalty Pharma (Nasdaq: RPRX) has announced a 6.8% increase in its quarterly dividend, raising it to $0.235 per Class A ordinary share for the first quarter of 2026. The dividend is scheduled for payment on March 10, 2026, to shareholders of record as of February 20, 2026. This move reflects the company's continuous funding of innovation in the biopharmaceutical industry.
Royalty Pharma Increases Quarterly Dividend to $0.235 a Share From $0.22, Payable March 10 to Holders of Record on Feb. 20.
Royalty Pharma plc has declared an increase in its quarterly dividend for the first quarter of 2026, raising it to $0.235 per share from the previous $0.22. The dividend will be payable on March 10, 2026, to shareholders of record as of February 20, 2026. This announcement highlights the company's commitment to returning value to its shareholders.
Royalty Pharma increases quarterly dividend by 6.8% to $0.235
Royalty Pharma (NASDAQ:RPRX) has announced a 6.8% increase in its quarterly dividend to $0.235 per Class A ordinary share, marking its sixth consecutive year of dividend raises. The dividend is set to be paid on March 10, 2026, to shareholders of record as of February 20, 2026. This decision follows recent strategic acquisitions by the company, including royalty interests in Roche's Evrysdi and new cancer therapies, alongside a positive outlook from TD Cowen.
Royalty Pharma Declares Q1 2026 Dividend of $0.235 per Share, Marking 6.8% Increase
Royalty Pharma plc announced a first-quarter 2026 dividend of $0.235 per Class A ordinary share, representing a 6.8% increase from the previous quarter. The dividend is scheduled for payment on March 10, 2026, to shareholders of record by February 20, 2026. This increase reflects the company's financial strength and its strategic position as a major buyer of biopharmaceutical royalties, supporting innovation across the industry.
Royalty Pharma Declares Q1 2026 Dividend of $0.235 per Share, Marking 6.8% Increase
Royalty Pharma plc announced a first-quarter 2026 dividend of $0.235 per Class A ordinary share, representing a 6.8% increase from the prior quarter. The dividend is scheduled for payment on March 10, 2026, to shareholders of record as of February 20, 2026. This move highlights the company's financial strength and its role as a major buyer of biopharmaceutical royalties, funding innovation across the industry with a portfolio spanning over 35 commercial products.
Royalty Pharma Announces Dividend Increase
Royalty Pharma plc announced a 6.8% increase in its quarterly dividend for the first quarter of 2026, raising it to $0.235 per Class A ordinary share. The dividend will be paid on March 10, 2026, to shareholders recorded by February 20, 2026. This reflects the company's continued financial performance and its role as a major funder of biopharmaceutical innovation.
Los Angeles Daily News - Royalty Pharma Announces Dividend Increase
Royalty Pharma plc announced a 6.8% increase in its quarterly dividend, setting it at $0.235 per Class A ordinary share for the first quarter of 2026. This dividend will be paid on March 10, 2026, to shareholders of record as of February 20, 2026. The company, founded in 1996, specializes in acquiring biopharmaceutical royalties and funding innovation within the biopharmaceutical industry.
Royalty Pharma Announces Dividend Increase
Royalty Pharma plc announced a 6.8% increase in its quarterly dividend for the first quarter of 2026, setting it at $0.235 per Class A ordinary share. The dividend will be paid on March 10, 2026, to shareholders of record as of February 20, 2026. Royalty Pharma is a major buyer of biopharmaceutical royalties and funds innovation across the industry, holding royalties on over 35 commercial products and 19 development-stage candidates.
What's Going On With Royalty Pharma Stock Wednesday?
Royalty Pharma's stock has gained 53% year-to-date. This article details Royalty Pharma's recent acquisition of PTC Therapeutics' royalty on Roche's Evrysdi for up to $300 million and their previous acquisition of a royalty interest in Nuvalent Inc.'s neladalkib and zidesamtinib for up to $315 million. It also outlines the competitive landscape for spinal muscular atrophy treatments and the sales projections for the acquired drug royalties.
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million
Royalty Pharma has acquired a pre-existing royalty interest in Nuvalent’s oncology drugs, neladalkib and zidesamtinib, for up to $315 million. These next-generation tyrosine kinase inhibitors are in development for NSCLC, with neladalkib showing positive pivotal results and zidesamtinib currently under FDA review. Analysts project significant sales for both therapies by 2035, securing Royalty Pharma a low-single-digit royalty on worldwide net sales until approximately 2041-2042.
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million
Royalty Pharma plc announced the acquisition of a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib for up to $315 million. These next-generation tyrosine kinase inhibitors are in development for ALK and ROS1 mutation-positive non-small cell lung cancer, respectively. The transaction covers a low-single digit royalty on worldwide net sales for both therapies, with an expected duration extending through approximately 2041 to 2042.
Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million
Royalty Pharma has acquired a royalty interest in Nuvalent's next-generation therapies, neladalkib and zidesamtinib, for up to $315 million. These drugs target different forms of non-small cell lung cancer and have shown promising clinical results, with analysts projecting significant sales by 2035. The acquisition is expected to provide Royalty Pharma with low-single digit royalties on worldwide net sales, extending through approximately 2041-2042.
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
Advances in novel therapies are accelerating survival gains for pancreatic cancer patients. Oncolytics Biotech Inc. is preparing for a pivotal Phase 3 study of pelareorep, an immunotherapy, in first-line metastatic pancreatic cancer, while Immuneering Corporation and Tango Therapeutics, Inc. have reported promising clinical data for their respective treatments. Moderna and Royalty Pharma plc are also investing in and supporting oncology advancements.
Royalty Pharma EVP Coyne sells shares worth $2.77 million By Investing.com
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc (NASDAQ:RPRX), sold 69,582 Class A Ordinary Shares for approximately $2.77 million on December 1, 2025. This transaction was conducted under a pre-arranged 10b5-1 trading plan. Despite Coyne's share sale, Royalty Pharma recently reported robust Q3 2025 financial results and raised its full-year guidance, leading to a positive adjustment in its price target by Goldman Sachs.
Royalty Pharma EVP Coyne sells shares worth $2.77 million By Investing.com
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold 69,582 Class A Ordinary Shares for approximately $2.77 million on December 1, 2025. These transactions were conducted under a pre-arranged 10b5-1 trading plan. This sale follows recent positive financial results for Royalty Pharma, including an 11% increase in third-quarter portfolio receipts and raised full-year guidance.
Royalty Pharma EVP Coyne sells shares worth $2.77 million
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc (NASDAQ:RPRX), sold 69,582 Class A Ordinary Shares for approximately $2.77 million on December 1, 2025. These transactions were executed under a pre-arranged 10b5-1 trading plan. The sale occurred amidst Royalty Pharma reporting robust Q3 2025 financial results and raising its full-year guidance.
Royalty Pharma EVP Coyne sells shares worth $2.77 million By Investing.com
Terrance P. Coyne, Executive Vice President and CFO of Royalty Pharma plc, sold 69,582 Class A Ordinary Shares for approximately $2.77 million on December 1, 2025. These transactions were executed under a pre-arranged 10b5-1 trading plan. Despite Coyne's share sale, Royalty Pharma reported strong Q3 2025 financial results and raised its full-year guidance, leading Goldman Sachs to adjust its price target upwards.
Urist Marshall sells Royalty Pharma (RPRX) shares worth $1.66 million By Investing.com
Urist Marshall, EVP of Research & Investments at Royalty Pharma plc (NASDAQ:RPRX), sold 41,575 shares totaling approximately $1.66 million on December 1, 2025. These sales were conducted under a 10b5-1 plan, with prices ranging from $39.60 to $40.06 per share. Following these transactions, Marshall's direct and indirect holdings in the company amount to 227,994 shares.
Royalty Pharma EVP Coyne sells $2.68 million in shares
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold 70,622 Class A Ordinary Shares totaling approximately $2.68 million on November 24, 2025, through a pre-arranged trading plan. Despite this insider selling, the company maintains a "GREAT" financial health score and an impressive 2.23% dividend yield, with management aggressively buying back shares. Royalty Pharma recently reported strong Q3 2025 financial results, raising its full-year guidance, leading Goldman Sachs to increase its price target for the stock to $45.
Earnings call transcript: Royalty Pharma Q3 2025 reports robust growth
Royalty Pharma (RPRX) reported robust financial results for Q3 2025, with portfolio receipts increasing 11% to $814 million, leading to a raised full-year guidance of $3.2 to $3.25 billion. The company emphasized its strategic investments, disciplined risk management in development-stage therapies, and strong return on invested capital and equity. Despite a slight premarket stock decline attributed to broader market trends, Royalty Pharma maintains a positive outlook, anticipating continued double-digit growth and shareholder value creation.
Royalty Pharma Reports Third Quarter 2025 Results
Royalty Pharma announced strong financial results for the third quarter of 2025, with an 11% increase in Portfolio Receipts and Royalty Receipts. The company expanded its portfolio through significant acquisitions and repurchases, and raised its full-year 2025 guidance, reflecting consistent growth and strategic capital allocation in life sciences.
Royalty Pharma plc SEC 10-Q Report
Royalty Pharma plc has released its latest Form 10-Q report, demonstrating strong financial and operational performance with significant growth in income and profitability. Key highlights include total income of $1,756.2 million and a consolidated net income of $968.3 million, driven by strategic investments and a diversified portfolio of biopharmaceutical royalty assets. The company continues to focus on strategic funding collaborations and acquisitions for future growth.
Royalty Pharma's Strong Portfolio Growth and Manager Acquisition Boost Long-Term Outlook
Royalty Pharma, the largest buyer of biopharmaceutical royalties, is poised for sustained growth due to its strong portfolio and recent manager acquisition. The company's unique business model, which involves lump-sum payments for future cash flows from product sales, differentiates it from traditional biotech firms by avoiding high R&D and manufacturing costs. This approach, coupled with the diversity of its royalty portfolio across various therapeutic areas, underpins a strong long-term outlook.
Royalty Pharma Acquires $310 Million Royalty Interest in Alnylam's AMVUTTRA from Blackstone Life Sciences
Royalty Pharma has acquired a 1% royalty interest in Alnylam Pharmaceuticals' AMVUTTRA for $310 million from Blackstone Life Sciences. This acquisition enhances Royalty Pharma's portfolio, as AMVUTTRA, an FDA-approved RNAi therapeutic for ATTR amyloidosis, generated approximately $1 billion in sales in 2024 and is projected to exceed $6 billion by 2028. The royalty extends through March 2035, providing a long-term revenue stream for Royalty Pharma.
How Royalty Pharma Prints Cash Without Biotech's Biggest Risks
Royalty Pharma (RPRX) has developed a unique business model that allows investors to participate in the biopharmaceutical industry's growth while mitigating significant risks. The company acquires royalty interests in approved and late-stage drugs, providing upfront capital to developers in exchange for a percentage of future sales. This strategy, coupled with diversification across numerous therapies, enables Royalty Pharma to generate stable cash flows, fund new investments, and return capital to shareholders through buybacks and dividends.
Royalty Pharma Sets Q3 2025 Dividend: Key Dates and Payment Details Revealed
Royalty Pharma (Nasdaq: RPRX) has announced a quarterly dividend payment of $0.22 per Class A ordinary share for the third quarter of 2025. The dividend is scheduled to be paid on September 10, 2025, to shareholders of record as of August 15, 2025. This decision reflects the company's consistent commitment to returning value to shareholders.
Royalty Pharma Reports Second Quarter 2025 Results
Royalty Pharma plc announced strong financial results for the second quarter of 2025, reporting significant increases in portfolio receipts and adjusted EBITDA. The company also raised its full-year guidance for 2025, reflecting robust performance from its diversified royalty portfolio and strategic initiatives, including the acquisition of its external manager and a new funding agreement with Revolution Medicines.
Nordea Investment Management AB Boosts Position in Royalty Pharma PLC $RPRX
Nordea Investment Management AB significantly increased its stake in Royalty Pharma PLC by 603.9% in the second quarter, acquiring an additional 562,799 shares. This move is part of a broader trend of hedge funds investing in Royalty Pharma, with institutional investors now holding 54.35% of the company's stock. Royalty Pharma also declared a quarterly dividend of $0.22 per share, reflecting a 2.4% annual yield.
Royalty Pharma PLC (NASDAQ:RPRX) to Issue Quarterly Dividend of $0.22 - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) has announced a quarterly dividend of $0.22 per share, payable on December 10th to shareholders of record on November 14th, resulting in an annualized yield of 2.4%. The company's dividend is well-covered by its earnings, with a payout ratio of 17.5% and expected future payout ratio of 18.1%. Analysts currently rate RPRX as a "Buy" with a consensus target price of $46.00.
Royalty Pharma Keeps Quarterly Dividend at $0.22 a Share, Payable Dec. 10 to Holders of Record on Nov. 14 - MarketScreener
Royalty Pharma plc announced that it is maintaining its quarterly dividend at $0.22 per share. The dividend is payable on December 10, 2025, to shareholders of record as of November 14, 2025.
